Priming after a fractional dose of inactivated poliovirus vaccine

New England Journal of Medicine

Volumn 368, Issue 5, 2013, Pages 416-424

  Resik, Sonia ^a   Tejeda, Alina ^b   Sutter, Roland W ^c   Diaz, Manuel ^a   Sarmiento, Luis ^a   Alemañi, Nilda ^b   Garcia, Gloria ^a   Fonseca, Magilé ^a   Hung, Lai Heng ^a   Kahn, Anna Lea ^c   Burton, Anthony ^c   Landaverde, J Mauricio ^d   Aylward, R Bruce ^c  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b Provincial Health Office   (Cuba)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d PAN AMERICAN HEALTH ORGANIZATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CUBA; DRUG DOSE COMPARISON; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INTERMETHOD COMPARISON; MALE; NEUTRALIZATION ASSAY; NORMAL HUMAN; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; POLIOMYELITIS VIRUS 2; POLIOMYELITIS VIRUS 3; PRIMING IMMUNE RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SEROCONVERSION; VIRUS INACTIVATION; VIRUS NEUTRALIZATION;

EID: 84873048082     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1202541     Document Type: Article

References (38)

1. World Health Assembly. Global eradication of poliomyelitis by the year 2000. Geneva: World Health Organization, 1988 (resolution WHA 11.28).
2. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep 2001;50:222-4. [Erratum, MMWR Morb Mortal Wkly Rep 2001;50:249].
3. Outbreaks following wild poliovirus importations - Europe, Africa, and Asia, January 2009-September 2010. MMWR Morb Mortal Wkly Rep 2010;59:1393-9.
4. Outbreak of poliomyelitis in Tajikistan in 2010: risk for importation and impact on polio surveillance in Europe? Euro Surveill 2010;15(17):pii=19558.
5. Grard G, Dexler JF, Lekana-Douki S, et al. Type 1 wild poliovirus and putative enterovirus 109 in an outbreak of acute flaccid paralysis in Congo, October-November 2010. Euro Surveill 2010;15(47):pii=19723.
6. Progress towards eradicating poliomyelitis in India, January 2009-October 2010. Wkly Epidemiol Rec 2010;85:497-503.
7. Progress towards global eradication of wild poliovirus transmission, January 2011-March 2012. Wkly Epidemiol Rec 2012;87:195-200.
8. Dove AW, Racaniello VR. The polio eradication effort: should vaccine eradication be next? Science 1997;277:779-80.
9. Conclusions and recommendations of the Ad Hoc Advisory Committee on Poliomyelitis Eradication, Geneva, 21-22 September 2004. Wkly Epidemiol Rec 2004;79:401-7.
10. Meeting of the Immunization Strategic Advisory Group of Experts, November 2008 - conclusions and recommendations. Wkly Epidemiol Rec 2009;84:1-16.
11. Polio Eradication Initiative. Cessation of routine oral polio vaccine (OPV) use after global polio eradication: framework for national policy makers in OPV-using countries. Geneva: World Health Organization, 2005 (WHO/POLIO/05.02).
12. Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis. "End-game" issues for the global polio eradication initiative. Clin Infect Dis 2002;34:72-7.
13. Bruce Aylward R, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann D. Risk management in a polio-free world. Risk Anal 2006;26:1441-8.
14. World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication. Geneva: World Health Organization, 2008 (resolution WHA 61.1).
15. Kreeftenberg H, van der Velden T, Kersten G, van der Heuvel N, de Bruijn M. Technology transfer of Sabin-IPV to new developing country markets. Biologicals 2006;34:155-8.
16. Simizu B, Abe S, Yamamoto H, et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 2006;34:151-4.
17. Liao G, Li R, Li C, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains (Sabin IPV): a phase-II randomized positive-controlled trial. J Infect Dis 2012;205:237-43.
18. Sutter RW, Cáceres VM, Mas Lago P. The role of routine polio immunization in the post-certification era. Bull World Health Organ 2004;82:31-9.
19. WHO Collaborative Study Group on Oral and Inactivated Polio Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, and Thailand. J Infect Dis 1997;175:Suppl 1:S215-S227.
20. Cohen-Abbo A, Culley BS, Reed GW, et al. Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Pediatr Infect Dis J 1995;14:100-6.
21. Resik S, Tejeda A, Mas Lago P, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010;201:1344-52.
22. Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010;362:2351-9.
23. Más Lago P, Gary HE Jr, Pérez LS, et al. Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. Int J Epidemiol 2003;32:772-7.
24. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. J Infect Dis 1995;171:1097-106.
25. Expanded Programme on Immunization. Report of a WHO informal consultation on polio neutralization antibody assays, Nashville, 5-6 December 1991. Geneva: World Health Organization, 1991 (WHO/EPI/RD/91.3 Rev 1).
26. Sutter RW, Kew OM, Cochi SL Aylward BA. Poliovirus vaccine - live. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Philadelphia: W.B. Saunders, 2012:598-645.
27. Sutter RW, Suleiman AJM, Malankar P, et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000;343:767-73.
28. R Development Core Team. R: a language and environment for computing. Vienna: R Foundation for Statistical Computing, 2006 (http://www.R-project.org).
29. SAS/STAT user's guide, version 6.4. 4th ed. Cary, NC: SAS Institute, 1989.
30. Conover WJ. Practical nonparametric statistics. New York: John Wiley & Sons, 1971.
31. Efron B, Tibshirani R. An introduction to the Bootstrap. London: Chapman & Hall/CRC, 1993.
32. Robertson SE, Traverso HP, Drucker JA, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988;1:897-9.
33. Kapusinszky B, Molnár Z, Szomor KN, Berencsi G. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunol Med Microbiol 2010;58:211-7.
34. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004;292:1696-701.
35. Sangrujee N, Cáceres VM, Cochi SL. Cost analysis of post-polio certification immunization policies. Bull World Health Organ 2004;82:9-15.
36. Griffiths UK, Botham L, Schoub BD. The cost-effectiveness of alternative polio immunization policies in South Africa. Vaccine 2006;24:5670-8.
37. Sutter RW, Mohammed AJ. Poliovirus vaccine and vaccine-derived poliovirus. N Engl J Med 2010;363:1870-1.
38. Böttiger M. A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years. Scand J Infect Dis 1987;19:595-601.